DT
Dragonfly Therapeutics
MA - Waltham
Biotechnology1 H-1B visas (FY2023)Focus: Immuno-oncology Drugs
Dragonfly Therapeutics is a life sciences company focused on Immuno-oncology Drugs.
Oncology
Funding Stage
PUBLIC
Open Jobs
1
Pipeline & Clinical Trials
Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test
Multiple SclerosisClinical Trials (1)
NCT04837651Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab
N/ADF6215
Solid Tumor, AdultDF5112
Healthy ParticipantsClinical Trials (1)
NCT07232121A Study to Evaluate the Safety of Increasing Doses of DF5112 in Healthy Adults
Phase 1DF6002
Solid TumorsClinical Trials (1)
NCT04423029A Study of DF6002 Alone and in Combination With Nivolumab
Phase 1DF9001
Solid Tumor, AdultDF1001
Solid Tumor, AdultClinical Trials (1)
NCT04143711Study of DF1001 in Patients with Advanced Solid Tumors
Phase 1/2Dragonfly™ Digital Pancreaticobiliary System
Bile Duct AdenocarcinomaClinical Trials (1)
NCT07120295Study of Large Channel Digital Pancreaticobiliary Scope (DPS) With Compatible Accessories
Phase 4Open Jobs (1)
Interview Prep Quick Facts
Founded: 2016
Portfolio: 5 clinical trials
H-1B (2023): 1 approval
Open Roles: 1 active job
Hiring Trend
Stable
1
Open Roles
+0
Added
-0
Filled/Removed
Based on last 4 crawl cycles
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub